Atrial Fibrillation Drugs Market: Overview

Atrial fibrillation is the most common sustained cardiac arrhythmia disorder across the globe. It is caused by degeneration of the electrical impulses in the upper cardiac chambers (atria) of the heart leading to chaotic rhythm. Advancing age, diabetes, high blood pressure, obesity, excessive alcohol consumption, chronic kidney disease, and ischemic heart disease are the major risk factors for atrial fibrillation. According to the American Heart Association, the lifetime risk of developing atrial fibrillation is 25% for individuals aged 40 years and above. Atrial fibrillation leads to increased hospitalization rate, impaired quality of life, and increased risk of stroke and death. Atrial fibrillation medications are used to control the heart rate and rhythm by preventing blood clots which leads to effective management of the disease. Warfarin, Apixaban, Sotalol, Esmalol, Verapamil, and Dofetilide are some of the atrial fibrillation drugs currently available in the market.

Atrial Fibrillation Drugs Market: Key Trends

Increase in the number of elderly patients and rise in prevalence of atrial fibrillation across the globe are the major factors driving the global atrial fibrillation drugs market. According to the Centers for Disease Control and Prevention (CDC), 2.7 million to 6.1 million people in the U.S. are suffering from atrial fibrillation and the number is expected to reach 12.1 million by 2030. This is projected to fuel the demand for atrial fibrillation drugs during the forecast period. Increase in the geriatric population is a major factor contributing to high prevalence of atrial fibrillation, which in turn is anticipated to propel the market in the next few years. For instance, prevalence of atrial fibrillation increases with age, affecting around 10% of the population aged 80 years and above. However, high cost of anticoagulants and complications associated with the use of atrial fibrillation drugs including shortness of breath, low blood pressure, seizures, slow heart rate, fainting, hallucinations, and heart palpitations are likely to restrain the global market from 2019 to 2027.

Atrial Fibrillation Drugs Market: Segmentation

The global atrial fibrillation drugs market can be segmented based on drug class, type, route of administration, end-user, and region. In terms of drug class, the market can be categorized into calcium channel blockers, beta-adrenergic receptor blockers, cardiac glycosides, antiarrhythmic drugs, anticoagulants, and antiplatelet agents. The anticoagulants segment held considerable share of the global market in 2018. Based on type, the global atrial fibrillation drugs market can be divided into paroxysmal, persistent, and long-standing atrial fibrillation. In terms of route of administration, the global market can be bifurcated into oral and injectable. Based on end-user, the global atrial fibrillation drugs can be classified into hospitals, ambulatory surgical centers, and others.

Atrial Fibrillation Drugs Market: Regional Analysis

The global atrial fibrillation drugs market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest share of the global market between 2019 and 2027. Rise in prevalence of cardiovascular diseases such as atrial fibrillation among the aging patient pool, presence of leading drug manufacturers in the U.S., and favorable reimbursement scenario for cardiac surgeries are anticipated to drive demand for atrial fibrillation drugs in the country. According to CDC, 9% of the geriatric population aged 65 and above has atrial fibrillation in the country. High geriatric patient pool with cardiac disorders and rise in prevalence of atrial fibrillation is expected to drive demand for atrial fibrillation therapeutics in Europe in the next few years. For instance, atrial fibrillation affects approximately 4.5 million people in countries in Europe. Rapid adoption of western lifestyle, which increases the risk of cardiac diseases, and surge in the baby boomer population suffering from cardiovascular ailments in the developing countries such as India and China are the key factors boosting the atrial fibrillation drugs market in Asia Pacific.

Atrial Fibrillation Drugs Market: Competitive Landscape

Key players operating in the global atrial fibrillation drugs market are Pfizer, GlaxoSmithKline, Johnson & Johnson, Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Acesion Pharma, and Bristol-Myers Squibb Co. These players focus on research and development activities for innovative product launches, as well as mergers & acquisitions to expand product portfolio and enhance geographic presence.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Atrial Fibrillation Drugs Market

Pre Book